Michael Yee

Brian Abrahams

Jay Olson

Rudy Li

Tazeen Ahmad

Umer Raffat

Charles Duncan

Emma Seymour

Jason Butler

Neena Bitritto-Garg

- Prothena announced results from its **Phase 1 ASCENT clinical program** for **PRX012**, an anti-amyloid beta antibody for early symptomatic Alzheimer’s disease.  **[1559053_9a59e3fb82bc4b34a945a2e2e84f9d5e_0]** 
- The program demonstrated **dose- and time-dependent reductions in amyloid plaque**, with the **400 mg dose** achieving a mean reduction in amyloid PET to **27.47 centiloids (CL)** at month 12.  **[1559053_9a59e3fb82bc4b34a945a2e2e84f9d5e_0]** **[1559053_9a59e3fb82bc4b34a945a2e2e84f9d5e_2]** 
- However, **PRX012** was associated with **higher overall ARIA-E rates** relative to FDA-approved anti-Aβ antibodies, making it less appropriate for the patients studied.  **[1559053_9a59e3fb82bc4b34a945a2e2e84f9d5e_0]** 
- Prothena plans to **explore potential partnership interest** to advance **PRX012** and its preclinical **PRX012-TfR (transferrin receptor) antibody**, which is being developed to potentially lower ARIA risk.  **[1559053_9a59e3fb82bc4b34a945a2e2e84f9d5e_0]**

Prothena Announces Phase 1 ASCENT Clinical Program Results for PRX012

PROTHENA CORP PUBLIC LTD (PRTA)